(4-Phosphonooxybenzoyl)oxymethyl 2-(2-oxo-1-phenylpropyl)piperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: (4-Phosphonooxybenzoyl)oxymethyl 2-(2-oxo-1-phenylpropyl)piperidine-1-carboxylate
• 英文别名: (4-phosphonooxybenzoyl)oxymethyl 2-(2-oxo-1-phenylpropyl)piperidine-1-carboxylate
• 化学式: C₂₃H₂₆NO₉P
• 分子量: 491.4
• InChiKey: WYWRYAVKIMETHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  140
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Methylphenidate-Prodrugs, Processes of Making and Using the Same
  申请人：KemPharm, Inc.

  公开号：US20150266911A1

  公开（公告）日：2015-09-24

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  目前的技术是针对前药和组合物的，用于治疗包括甲基苯丙胺或甲基苯丙胺衍生物的至少与醇、胺、羧酸、硫醇或其衍生物结合的各种疾病和/或紊乱。在某些实施例中，这些结合物还包括至少一个连接剂。该技术还涉及合成甲基苯丙胺或甲基苯丙胺衍生物，结合至少一个醇、胺、羧酸、硫醇或其衍生物或其组合的方法。
• METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME
  申请人：Guenther Sven

  公开号：US20140243291A1

  公开（公告）日：2014-08-28

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  本技术涉及用于治疗各种疾病和/或障碍的前药和组合物，包括将哌甲酯或哌甲酯衍生物与至少一种醇，胺，羧酸，硫醇或其衍生物结合。在某些实施例中，共轭物还包括至少一个连接剂。本技术还涉及合成哌甲酯或哌甲酯衍生物与至少一种醇，胺，羧酸，硫醇或其衍生物或其组合物结合的方法。
• US9079928B2
  申请人：——

  公开号：US9079928B2

  公开（公告）日：2015-07-14
• US9453037B2
  申请人：——

  公开号：US9453037B2

  公开（公告）日：2016-09-27